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Race, Calcineurin Inhibitor Exposure, and Renal Function After Solid
Organ Transplantation
L. Yessayana,b,*, A. Shaﬁqa, E. Petersonc, K. Wellsc, Y. Huc, L.K. Williamsa,c, and D. Lanfeara,c,d
a
Department of Internal Medicine, bDivision of Nephrology, cHeart and Vascular Institute, and dCenter for Health Services Research,
Henry Ford Hospital, Detroit, Michigan, United States

ABSTRACT
Background. Calcineurin-inhibitor (CNI)einduced nephrotoxicity frequently complicates
transplantation. African-Americans are at a greater risk of renal failure than the general
population. We investigated whether race was an effect modiﬁer of the relationship
between CNI exposure and kidney function after nonrenal solid organ transplantation.
Methods. This is a retrospective cohort study of 1609 patients who underwent initial
nonrenal solid organ transplantation between January 2000 and June 2012. A central repository administrative database was queried electronically for demographics, comorbidities, and serial levels of tacrolimus, cyclosporine, and serum creatinine. Predictors of
interest were total drug exposure of tacrolimus and cyclosporine (area under the
concentrationetime curve) and self-reported race. The outcome of interest was cumulative
change in estimated glomerular ﬁltration rate (GFR).
Results. There were 1109 patients treated with tacrolimus (271 African-Americans) and
500 patients treated with cyclosporine (113 African Americans). A decline in GFR
over time was seen with total tacrolimus exposure (1.3 mL/min/1.73 m2 for every
5 ng/mL$year increase in tacrolimus) and total cyclosporine exposure (1.1 mL/min/
1.73 m2 for every 50 ng/mL$year increase in cyclosporine). However, total CNI exposure
effect on estimated GFR changes did not vary by race (P interaction was 0.9 for
tacrolimus and 0.6 for cyclosporine).
Conclusions. Total CNI exposure is associated with worsening kidney function among
patients with nonrenal solid organ transplantation. However, African-American patients are
not more vulnerable to chronic CNI-induced nephrotoxicity when compared to white patients.

C

ALCINEURIN INHIBITORS (CNIs) such as cyclosporine and tacrolimus have made possible the modern
era of transplantation medicine, resulting in substantial
improvement in success rates after solid organ transplantation [1e3]. Unfortunately, these medications, which are
the cornerstone of post-transplantation immunosuppressive
therapy, carry with them a number of adverse side effects [4].
The nephrotoxic effects of cyclosporine and tacrolimus are a
major concern in solid organ transplantation and many other
diseases that require therapy with these drugs [2,5e7].
Calcineurin inhibitor exposure is associated with irreversible
changes in blood vessels (arterial hyalinosis), tubulointerstitium (tubular atrophy and interstitial ﬁbrosis), and
glomeruli (thickening and ﬁbrosis of Bowman’s capsule and
focal segmental or global glomerular sclerosis) [8e10].

Progressive renal dysfunction plagues recipients of solid
organ transplants with a 5-year risk of chronic renal failure
(deﬁned as glomerular ﬁltration rate [GFR] <30 mL/min/
1.73 m2) that ranges from 7% to 21%, depending on the type
of organ transplanted [6].
Post-transplantation graft and patient outcomes have
previously been shown to vary by recipient race [11e15],
which is thought to be due to a variety of issues ranging from
immune reactivity to access to medical care [16e18].
Moreover, African-Americans are known to disproportionately suffer from kidney disease, possibly due to high rates
*Address correspondence to Lenar Yessayan, MD, MS, Division of Nephrology, Henry Ford Hospital, 2799 W. Grand Blvd,
CFP-5, Detroit, MI 48202. E-mail: lyessay1@hfhs.org

0041-1345/15
http://dx.doi.org/10.1016/j.transproceed.2015.10.052

ª 2015 by Elsevier Inc. All rights reserved.
360 Park Avenue South, New York, NY 10010-1710

2968

Transplantation Proceedings, 47, 2968e2972 (2015)
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on February 25, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

RACE, CNI EXPOSURE, & RENAL FUNCTION AFTER TX

of coexisting hypertension and diabetes and access to health
care [19]. Despite this, whether there is racial disparity in
terms of the nephrotoxic effects of CNIs is not clear. The
very few studies that reported on racial differences in
chronic CNI-induced nephrotoxicity rates had several limitations, namely small number of patients, short period of
follow-up, and failure to account for degree of exposure.
With these considerations in mind, we conducted a large
retrospective study of patients with nonrenal solid organ
transplants to investigate whether the correlation of CNI
exposure (measured as area under the timeeconcentration
curve) and renal function differed by self-identiﬁed race.
MATERIAL AND METHODS
Study Population and Participants
We conducted a retrospective cohort study utilizing an
administrative-linked electronic database of patients in the Henry
Ford Health System in Michigan. The system includes several
hospitals, a multispecialty physician group of approximately 1000
physicians, and an afﬁliated health maintenance organization. The
system maintains a central repository of administrative data that we
queried for this study. Using electronic data sources, we identiﬁed
1609 patients 18 years of age or older who underwent initial solid
organ transplantation (cardiac, lung, or liver) between January 2000
and June 2012, and who survived the hospitalization and were
discharged. A master patient index contained demographic data
(i.e. date of birth, sex, and race). All subject-speciﬁc variables and
laboratory measurements were obtained from electronic medical
records. Patients who underwent renal transplantation were
excluded because the impact of CNI exposure on a transplanted
kidney may differ from that of a native kidney. Creatinine level at
discharge from transplantation hospitalization was considered
baseline. The observation period for each individual lasted from
discharge until the time of death, loss to follow-up, or onset of
dialysis. The study was approved by the Henry Ford Hospital
Institutional Review Board.

Outcome of Interest
The outcome of interest was the cumulative change in estimated
GFR (eGFR). Cumulative change in eGFR for each individual was
deﬁned as the sum of the differences between any observed eGFR
and baseline eGFR. The 4-variable Modiﬁcation of Diet in Renal
Disease study equation was used to calculate eGFR.

Primary Predictors
The predictors of interest were total tacrolimus exposure, total
cyclosporine exposure (area under concentration-time curve), and
self-reported race. Total CNI exposure was deﬁned as the sum of
areas under the curves between 2 consecutive CNI levels over time.

Covariates of Interest
Covariates of interest were age, sex, eGFR on day of discharge from
the hospital post-transplantation, diabetes, and hypertension. Age
reﬂected the measurement at the date of transplantation. Sex was
determined by self-report. Hypertension and diabetes were determined through electronic medical records based on International
Classiﬁcation of Diseases, Ninth Revision (ICD-9) codes.
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Statistical Analysis
We used generalized estimating equations to test the association between total cumulative tacrolimus or cyclosporine exposure over time
and cumulative changes in eGFR from baseline, including adjustment
for age, gender, hypertension, diabetes, and baseline kidney function.
The data from each individual consisted of changes in cumulative
changes in eGFR from any measure to baseline and an area under the
curve, from measure to measure, for the drug in question. To relate
the two, a linear regression model was implemented using a generalized estimating equation approach. This approach was used to model
the correlation within the cluster of values for an individual. c2 tests
for categorical variables and Student t test for continuous variables
were used to compare the groups in Table 1. P values <.05 were
considered positive for main effects. P < .1 was considered positive for
interaction of either CNI with race. All analyses were performed using
SAS 9.4 (SAS Institute Inc., Cary, N.C., United States).

RESULTS

Of the 1609 patients identiﬁed, 1109 patients were treated
with tacrolimus (271 African-Americans) and 500 were
treated with cyclosporine (113 African-Americans) (Fig 1).
Demographics and baseline characteristics stratiﬁed by race
are shown in Table 1. History of hypertension was more
prevalent in African-Americans than whites. AfricanAmericans were younger, had a higher proportion of females, and slightly higher eGFRs than whites. Multivariate
modeling adjusted for age, gender, hypertension, diabetes,
and baseline kidney function showed that total tacrolimus
and cyclosporine exposure over time were associated with
eGFR decline (P < .001) but this effect did not vary by race
for either drug (Pinteraction ¼ .9 for cross-product term of total
tacrolimus exposure and race; Pinteraction ¼ .6 for cross
product term of total cyclosporine exposure and race).
Tables 2 and 3 show the multivariate models for the association between cumulative changes in eGFR and total exposure to tacrolimus/cyclosporine. For each 5 ng/mL$years of
tacrolimus exposure, the eGFR decreased by approximately
1.3 mL/min/1.73 m2. For each 50 ng/mL$years of cyclosporine exposure, the eGFR decreased by approximately
1.1 mL/min/1.73 m2.
DISCUSSION

The introduction of CNIs has revolutionized transplantation
medicine. They are now widely used as immunosuppressant
Table 1. Clinical Characteristics Stratiﬁed by Race
Whites
n ¼ 1225

Hypertension, n (%)
Diabetes, n (%)
Female, n (%)
Age (y), mean  SD
Baseline GFR (mL/min/1.73 m2),
mean  SD
Creatinine (mg/dL), mean  SD

African Americans
P
n ¼ 384
Value

81 (6.6)
273 (22.3)
427 (34.9)
54.4  10
82.9  42.6

43 (11.2)
89 (23.2)
164 (42.7)
49.9  11.6
93.9  59.8

.003
.715
.005
.001
.001

1.20  0.91

1.22  0.67

.003

Conversion factors for units: serum creatinine in mg/dL to mmol/L, 88.4.
Abbreviations: GFR, glomerular ﬁltration rate; SD, standard deviation.
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Table 3. Multivariate Model Showing Association of Cumulative
eGFR Change and Total Cyclosporine Exposure After Adjusting
for Race, Gender, Age, Hypertension, Diabetes, and Baseline
Glomerular Filtration Rate

1,609 nonrenal solid
organ transplant

Tacrolimus

1,109

271
African American

Cumulative eGFR Change
(mL/min/1.73 m2)

cyclosporine

500

838
White

113
African American

387
White

Fig 1. Number of patients exposed to either cyclosporine or
tacrolimus by self-identiﬁed race.

therapy for liver, renal, cardiac, and lung transplantation.
Patients treated with the CNIs cyclosporine and tacrolimus
are at a high risk of developing renal injury [20]. Nephrotoxicity can be divided into acute and chronic forms. Acute
nephrotoxicity is primarily associated with profound alterations in vascular ﬂow [21e23] and vasoconstriction of preglomerular afferent arterioles [24] and is largely reversible
after reducing the dose. Other forms of acute nephrotoxicity
include tubular dysfunction and rarely thrombotic microangiopathy/hemolytic uremic syndrome [25e27]. Chronic
CNI-induced nephrotoxicity, which is usually irreversible,
results from arteriolar hyalinosis, tubular atrophy, interstitial
ﬁbrosis, and glomerular sclerosis [28e31]. It remains quite
difﬁcult to recognize patients who are most likely to develop
chronic CNI-induced kidney nephrotoxicity.
African American patients have an unequal share of renal
disease. Suggested explanations for this racial disparity
include a higher prevalence of diabetes mellitus and hypertension among African Americans [32e35], increased
inherited predisposition of African Americans to kidney
damage [36,37], and lower socioeconomic status among
African Americans [38e40]. Racial differences with regards
to the effects of CNI-induced nephrotoxicity have not been
Table 2. Multivariate Model Showing Association of Cumulative
eGFR Change and Total Tacrolimus Exposure After Adjusting for
Race, Gender, Age, Hypertension, Diabetes, and Baseline
Glomerular Filtration Rate
Cumulative eGFR Change
(mL/min/1.73 m2)
Variable

Estimate  SD

P Value

Tacrolimus exposure
(per 5 ng/mL$year increase)
African Americans
Female
Age (per 10-year increase)
Hypertension
Diabetes
Baseline eGFR (mL/min/1.73 m2)

1.30  0.22

.001

4.95
5.00
4.05
11.2
4.12
0.45








2.50
1.97
1.08
2.28
1.76
0.05

.048
.010
.001
.001
.019
.001

Abbreviations: eGFR, estimated glomerular ﬁltration rate; SD, standard
deviation.

Variable

Estimate  SD

P value

Cyclosporine exposure
(per 50 ng/mL$year increase)
African Americans
Female
Age (per 10-year increase)
Hypertension
Diabetes
Baseline eGFR (mL/min/1.73 m2)

1.13  0.15

.001

3.88
8.57
7.34
6.42
0.61
0.61








3.02
2.47
1.38
2.61
2.40
0.03

.199
.001
.001
.014
.798
.001

Abbreviations: eGFR, estimated glomerular ﬁltration rate; SD, standard
deviation.

investigated in detail. We performed a literature search and
found no large cohort studies that reported on racial differences in the renal toxic effects of CNIs.
The 3 studies that we came across all had small patient
numbers and short analytical horizons, and none were
primarily designed to evaluate ethnic variation in kidney
dysfunction. Two of these studies were in kidney transplant
patients in whom, in addition to CNI-induced nephrotoxicity, a variety of other causes could have contributed to
progressive kidney dysfunction, such as recurrence of primary kidney disease and acute or chronic rejection. In 1
multicenter randomized clinical trial of 205 (25% African
Americans) designed primarily to compare patient survival
and renal graft survival between recipients of cyclosporine
and tacrolimus, the serum creatinine levels were similar
across race and treatment groups through 1 year after
transplantation [41]. In another prospective study of 63
heart transplant patients (63% African Americans)
designed primarily to compare acute rejection, patient
survival, and renal graft survival of tacrolimus and mycophenolate regimens, no differences in renal function were
noted at 1 year in the tacrolimus-treated African American
or white groups [42]. Finally, a retrospective study of 114
patients (24% African American) evaluated acute rejection rates of kidney transplant between African American
and white patients receiving a combination of tacrolimus,
sirolimus, and corticosteroids. Although the long-term
survival rates were low in the African American patients
when compared to the white patients, there was no
signiﬁcant difference in the renal toxicity effects in both
races [43].
From the review of these studies, we found that there has
been no extensive study in a large patient population to
determine the racial differences in terms of the exposure to
tacrolimus and cyclosporine. We studied 1609 nonrenal
solid organ transplant patients and the results showed that
total CNI exposure was associated with worsening kidney
function. However, these patients were not more susceptible
to the effects of CNIs when compared to whites. In contrast
to other studies in which kidney function at speciﬁc time
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points between 2 races were compared without adjustment
for total drug exposure, we studied the effects of total CNI
exposure on kidney function, measured as area under the
concentration-time curve. We chose total area under the
curve as opposed to total amount of CNI administered as a
surrogate of total exposure because of unpredictable
doseeconcentration relationship with CNIs [44,45] and
variability in absorption, metabolism, and elimination of
these compounds [46e51].
Our study has several limitations. The observational nature
of our investigation renders the study subject selection to bias
and confounding. We tried to limit selection bias by including
all patients between the speciﬁed dates with no restriction for
inclusion. Potential for confounding was addressed by
adjusting for several factors known to affect renal function,
speciﬁcally age, blood pressure, and diabetes status. In
addition, we excluded kidney transplant patients considering
that the impact of CNI exposure on a transplanted kidney
may differ from that of a native kidney. Moreover, African
American kidney transplant patients have higher rates of
acute kidney rejection and this may potentially confound the
association of CNIs on eGFR and the relationship to race
(i.e. changes in eGFR could be due to CNI or rejection). Our
study was based on electronic administrative data, and thus
information on comorbidities is dependent on accurate
coding; however, this would not be expected to yield a systematic error that would affect our analysis and this approach
brings the advantage of adequate sample size. We did not
examine episodes of acute kidney injury, which likely feature
a different pathophysiology, so this cannot be commented
upon within the current work. Finally, because no routine
kidney biopsies are performed in nonrenal transplant recipients, no data are available on histologic changes to support a deﬁnite diagnosis of CNI nephrotoxicity.
In conclusion, cumulative CNI exposure was associated
with GFR decline; however, this did not differ by selfidentiﬁed race. Speciﬁcally, African American patients do
not appear to be more vulnerable to CNI-induced chronic
renal dysfunction when compared to white patients.
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